Stockreport

Summit boosts Instil, BioNTech as lead drug beats Merck's Keytruda [Seeking Alpha]

Instil Bio, Inc.  (TIL) 
NASDAQ:AMEX Investor Relations: nasdaq.com/symbol/til
PDF anti-PD-1 therapy Keytruda in a late-stage trial, Instil Bio ( NASDAQ: TIL ) and BioNTech ( NASDAQ: BNTX ), which develop similar drugs, have recorded sharp gains. Sha [Read more]